|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 1194044-20-6 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
| 常用名 | (4S)-4-[2,4-二氟-5-(5-嘧啶)苯基]-5,6-二氢-4-甲基-4H-1,3-噻嗪-2-胺 | 英文名 | LY2811376 |
|---|---|---|---|
| CAS号 | 1194044-20-6 | 分子量 | 320.360 |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | 486.5±55.0 °C at 760 mmHg |
| 分子式 | C15H14F2N4S | 熔点 | N/A |
| MSDS | N/A | 闪点 | 248.0±31.5 °C |
LY2811376 是一种可口服的，非肽段的 β-secretase (BACE1) 抑制剂，IC50 值为 239 nM-249 nM，能够降低 Aβ 蛋白的分泌，EC50值为 300 nM。
Fields of Application :
LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM.
| CAS Number: | 1194044-20-6 |
| Purity: | >98% |
| Molecular Weight: | 320.36 |
| Molecular Formula: | C15H14F2N4S |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | LY 2811376;LY-2811376 |
| Chemical Name: | |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
LY2811376 is a BACE1 inhibitor with marked Ab-lowering effects in animal models. Oral administration of LY2811376 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99 and sAPPb. Brain Abeta levels were decreased 50% relative to vehicle-treated groups three hours after a 10 mg/kg dose of LY2811376. LY2811376 has pharmacologic properties sufficient to elicit robust BACE1 inhibition in vivo. The first orally available non-peptidic β-secretase inhibitor, LY2811376, was identified by fragment-based screening, lowered Aβ levels in a mouse model of Alzheimer's disease as well as in normal dogs. In healthy volunteers LY2811376 was safe and well tolerated and produced long-lasting reductions in Aβ levels. LY2811376 produced sustained and robust reductions in plasma and CSF Ab in subjects, confirming proof of mechanism. While the clinical development of LY2811376 is on hold, development of potent, clinically well-tolerated BACE1 inhibitors For the treatment of Alzheimer's disease appears plausible.For the detailed information of LY2811376, the solubility of LY2811376 in water, the solubility of LY2811376 in DMSO, the solubility of LY2811376 in PBS buffer, the animal experiment (test) of LY2811376, the cell expriment (test) of LY2811376, the in vivo, in vitro and clinical trial test of LY2811376, the EC50, IC50,and Affinity of LY2811376, Please contact DC Chemicals.
